Header Logo

Connection

AARON THRIFT to Humans

Back to Details
This is a "connection" page, showing publications AARON THRIFT has written about Humans.
AARON THRIFT
Connection Strength
2.427
Humans
  1. Differences in gene expression may contribute to the racial differences in the risk of MASLD. PLoS One. 2026; 21(5):e0345383.
    View in: PubMed
    Score: 0.026
  2. The Association Between Physical Activity, Sedentary Time, and Sleep with Risk of Hepatocellular Carcinoma in Patients with Cirrhosis. Dig Dis Sci. 2026 Apr; 71(4):1522-1529.
    View in: PubMed
    Score: 0.025
  3. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2026 Jan; 36(1):49-68.
    View in: PubMed
    Score: 0.025
  4. Seroprevalence of Helicobacter pylori Infection Among Asymptomatic Patients Served by a Safety-Net Healthcare System. Clin Gastroenterol Hepatol. 2026 May; 24(5):1289-1297.
    View in: PubMed
    Score: 0.025
  5. Self-Collection for Primary HPV Testing: Acceptability in a Large Urban Emergency Department. Ann Emerg Med. 2025 Mar; 85(3):249-257.
    View in: PubMed
    Score: 0.024
  6. Trends and Variations in Pancreatic Cancer Mortality Among US Metro and Nonmetro Adults, 1999-2020. J Clin Gastroenterol. 2024 Jul 01; 58(6):627-631.
    View in: PubMed
    Score: 0.023
  7. Joint association of drinking alcohol and obesity in relation to cancer risk: A systematic review and data synthesis. Cancer Epidemiol. 2024 Aug; 91:102596.
    View in: PubMed
    Score: 0.023
  8. Patient- and system-level factors associated with racial/ethnic disparities in the delivery of guideline-concordant therapy among US?patients with gastric cancer. J Surg Oncol. 2024 Jun; 129(8):1542-1553.
    View in: PubMed
    Score: 0.023
  9. PNPLA3, Obesity, and Heavy Alcohol Use in Cirrhosis Patients May Exert a Synergistic Increase Hepatocellular Carcinoma Risk. Clin Gastroenterol Hepatol. 2024 Sep; 22(9):1858-1866.e4.
    View in: PubMed
    Score: 0.023
  10. An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients. Dig Dis Sci. 2024 Jul; 69(7):2430-2436.
    View in: PubMed
    Score: 0.023
  11. Somatic mutations of esophageal adenocarcinoma: a comparison between Black and White patients. Sci Rep. 2024 04 18; 14(1):8988.
    View in: PubMed
    Score: 0.023
  12. Response to letter entitled: Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2024 Jun; 204:114041.
    View in: PubMed
    Score: 0.023
  13. Recent Trends in the Incidence of Gastric Cancer in the United States. J Clin Gastroenterol. 2024 01 01; 58(1):39-45.
    View in: PubMed
    Score: 0.022
  14. Disparities in cancer mortality patterns: A comprehensive examination of U.S. rural and urban adults, 1999-2020. Cancer Med. 2023 Sep; 12(18):18988-18998.
    View in: PubMed
    Score: 0.022
  15. Racial/Ethnic Disparities in Cervical Cancer Stage at Diagnosis: Mediating Effects of Neighborhood-level Socioeconomic Deprivation. Cancer Epidemiol Biomarkers Prev. 2023 06 01; 32(6):818-824.
    View in: PubMed
    Score: 0.021
  16. Validation of a pre-endoscopy risk score for predicting the presence of gastric intestinal metaplasia in a U.S. population. Gastrointest Endosc. 2023 10; 98(4):569-576.e1.
    View in: PubMed
    Score: 0.021
  17. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023 05; 20(5):338-349.
    View in: PubMed
    Score: 0.021
  18. Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score. PLoS One. 2023; 18(2):e0282309.
    View in: PubMed
    Score: 0.021
  19. Trends and Racial/Ethnic Differences in Predictors of Cervical Cancer Screening among US Women Ages 30-64 Years. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):82-90.
    View in: PubMed
    Score: 0.021
  20. Preventable causes of cancer in Texas by race/ethnicity: Major modifiable risk factors in the population. PLoS One. 2022; 17(10):e0274905.
    View in: PubMed
    Score: 0.021
  21. Using Natural Language Processing to Automatically Identify Dysplasia in Pathology Reports for Patients With Barrett's Esophagus. Clin Gastroenterol Hepatol. 2023 05; 21(5):1198-1204.
    View in: PubMed
    Score: 0.020
  22. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Cancer. 2022 Sep; 173:250-262.
    View in: PubMed
    Score: 0.020
  23. Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2023 08; 21(9):2418-2420.e3.
    View in: PubMed
    Score: 0.020
  24. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol. 2023 05; 21(5):1314-1322.e5.
    View in: PubMed
    Score: 0.020
  25. Polygenic Risk Scores for Follow Up After Colonoscopy and Polypectomy: Another Tool for Risk Stratification and Planning Surveillance? Clin Gastroenterol Hepatol. 2023 01; 21(1):29-32.
    View in: PubMed
    Score: 0.020
  26. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023 05; 21(5):1252-1260.e5.
    View in: PubMed
    Score: 0.020
  27. Mediating Effects of Neighborhood-Level Socioeconomic Deprivation on the Association Between Race/Ethnicity and Advanced Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1402-1409.
    View in: PubMed
    Score: 0.020
  28. Increasing Incidence of Gallbladder Cancer among Non-Hispanic Blacks in the United States: A Birth Cohort Phenomenon. Cancer Epidemiol Biomarkers Prev. 2022 07 01; 31(7):1410-1417.
    View in: PubMed
    Score: 0.020
  29. Missed Opportunities for Screening or Surveillance Among Patients with Newly Diagnosed Non-cardia Gastric Adenocarcinoma. Dig Dis Sci. 2023 03; 68(3):761-769.
    View in: PubMed
    Score: 0.020
  30. Admixture Mapping in African Americans Identifies New Risk Loci for HCV-Related Cirrhosis. Clin Gastroenterol Hepatol. 2023 04; 21(4):1023-1030.e39.
    View in: PubMed
    Score: 0.020
  31. Inverse Association Between Gluteofemoral Obesity and Risk of Non-Cardia Gastric Intestinal Metaplasia. Clin Gastroenterol Hepatol. 2023 01; 21(1):64-71.
    View in: PubMed
    Score: 0.020
  32. Sociodemographic and Facility-Related Disparities in the Delivery of Guideline-Concordant Therapy Among Patients With Esophageal Adenocarcinoma. JCO Oncol Pract. 2022 07; 18(7):e1181-e1197.
    View in: PubMed
    Score: 0.020
  33. Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most. Am J Gastroenterol. 2022 07 01; 117(7):1056-1062.
    View in: PubMed
    Score: 0.020
  34. Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. Am J Gastroenterol. 2022 02 01; 117(2):280-287.
    View in: PubMed
    Score: 0.020
  35. Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S. Ethn Health. 2023 02; 28(2):299-312.
    View in: PubMed
    Score: 0.020
  36. Associations of Duration, Intensity, and Quantity of Smoking With Risk of Gastric Intestinal Metaplasia. J Clin Gastroenterol. 2022 01 01; 56(1):e71-e76.
    View in: PubMed
    Score: 0.019
  37. Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of U.S. adults using NHANES 2017-2018. Prev Med. 2022 01; 154:106903.
    View in: PubMed
    Score: 0.019
  38. Risk Score Using Demographic and Clinical Risk Factors Predicts Gastric Intestinal Metaplasia Risk in a U.S. Population. Dig Dis Sci. 2022 09; 67(9):4500-4508.
    View in: PubMed
    Score: 0.019
  39. Alcohol consumption and the risk of gastric intestinal metaplasia in a U.S. Veterans population. PLoS One. 2021; 16(11):e0260019.
    View in: PubMed
    Score: 0.019
  40. Trends in the incidence of early-onset colorectal cancer in all 50 United States from 2001 through 2017. Cancer. 2022 01 15; 128(2):299-310.
    View in: PubMed
    Score: 0.019
  41. Preventable causes of cancer in Texas by race/ethnicity: tobacco smoking. Epidemiol Health. 2021; 43:e2021046.
    View in: PubMed
    Score: 0.019
  42. Gastric Cancer Epidemiology. Gastrointest Endosc Clin N Am. 2021 Jul; 31(3):425-439.
    View in: PubMed
    Score: 0.019
  43. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017-2018. PLoS One. 2021; 16(6):e0252164.
    View in: PubMed
    Score: 0.019
  44. Modest Impact of Liver Transplantation on Hepatocellular Carcinoma Mortality in the United States, Findings from The Transplant Cancer Match (TCM) Study. Cancer Epidemiol Biomarkers Prev. 2021 03; 30(3):435-437.
    View in: PubMed
    Score: 0.018
  45. Global burden and epidemiology of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol Hepatol. 2021 06; 18(6):432-443.
    View in: PubMed
    Score: 0.018
  46. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021 Apr; 32(4):317-325.
    View in: PubMed
    Score: 0.018
  47. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma: Implications for Screening and Surveillance. Gastrointest Endosc Clin N Am. 2021 Jan; 31(1):1-26.
    View in: PubMed
    Score: 0.018
  48. Racial/Ethnic Differences in Cancers Attributable to Preventable Infectious Agents in Texas, 2015. Public Health Rep. 2020 Nov/Dec; 135(6):805-812.
    View in: PubMed
    Score: 0.018
  49. Response to Zhu and Xu. Am J Gastroenterol. 2020 10; 115(10):1725.
    View in: PubMed
    Score: 0.018
  50. External Validation of Four Point-of-Care Noninvasive Scores for Predicting Advanced Hepatic Fibrosis in a Predominantly Hispanic NAFLD Population. Dig Dis Sci. 2021 07; 66(7):2387-2393.
    View in: PubMed
    Score: 0.018
  51. Does Risk of Progression from Barrett's Esophagus to Esophageal Adenocarcinoma Change Based on the Number of Non-dysplastic Endoscopies? Dig Dis Sci. 2021 06; 66(6):1965-1973.
    View in: PubMed
    Score: 0.018
  52. Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. Dig Dis Sci. 2021 05; 66(5):1669-1672.
    View in: PubMed
    Score: 0.017
  53. Dietary Factors and Gastric Intestinal Metaplasia Risk Among US Veterans. Dig Dis Sci. 2021 05; 66(5):1600-1610.
    View in: PubMed
    Score: 0.017
  54. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020 07; 52(1):20-36.
    View in: PubMed
    Score: 0.017
  55. Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. J Natl Cancer Inst. 2020 05 01; 112(5):533-539.
    View in: PubMed
    Score: 0.017
  56. Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2021 05; 19(5):876-884.
    View in: PubMed
    Score: 0.017
  57. Demographic and Lifestyle Risk Factors for Gastric Intestinal Metaplasia Among US Veterans. Am J Gastroenterol. 2020 03; 115(3):381-387.
    View in: PubMed
    Score: 0.017
  58. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci. 2020 09; 65(9):2691-2699.
    View in: PubMed
    Score: 0.017
  59. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
    View in: PubMed
    Score: 0.017
  60. Preventable causes of cancer in Texas by race/ethnicity: Alcohol consumption. Alcohol. 2020 06; 85:21-26.
    View in: PubMed
    Score: 0.017
  61. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020 03; 18(3):534-542.
    View in: PubMed
    Score: 0.016
  62. Risk and Predictors of Esophageal and Stomach Cancers in HIV-Infected Veterans: A Matched Cohort Study. J Acquir Immune Defic Syndr. 2019 07 01; 81(3):e65-e72.
    View in: PubMed
    Score: 0.016
  63. Authors' reply to: Statin use and risk of liver cancer. Int J Cancer. 2019 10 01; 145(7):2009.
    View in: PubMed
    Score: 0.016
  64. Factors associated with favorable survival outcomes for Asians with hepatocellular carcinoma: A sequential matching cohort study. PLoS One. 2019; 14(4):e0214721.
    View in: PubMed
    Score: 0.016
  65. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019 09; 17(10):2117-2125.e3.
    View in: PubMed
    Score: 0.016
  66. Ancestry and Risk of Hepatic Fibrosis and Inflammation in Patients With HCV Infection. Clin Gastroenterol Hepatol. 2019 08; 17(9):1912-1914.
    View in: PubMed
    Score: 0.016
  67. Helicobacter pylori Infection and Gastroesophageal Reflux Disease-Barrett's Esophagus-Esophageal Adenocarcinoma Sequence: Reply From Authors. Am J Gastroenterol. 2018 11; 113(11):1724-1725.
    View in: PubMed
    Score: 0.016
  68. Editorial: less acid, less cancer? Is this the question? Authors' reply. Aliment Pharmacol Ther. 2018 10; 48(8):878-879.
    View in: PubMed
    Score: 0.016
  69. Time to Tailor Surveillance Intervals of Nondysplastic Barrett's Esophagus According to Segment Length and Persistence Over Multiple Endoscopies. Clin Gastroenterol Hepatol. 2019 04; 17(5):832-834.
    View in: PubMed
    Score: 0.015
  70. Prior Diagnosis of Barrett's Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018 11; 63(11):3112-3119.
    View in: PubMed
    Score: 0.015
  71. Barrett's Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? Dig Dis Sci. 2018 Aug; 63(8):1988-1996.
    View in: PubMed
    Score: 0.015
  72. Underuse of Surgery Accounts for Racial Disparities in Esophageal Cancer Survival Times: A Matched Cohort Study. Clin Gastroenterol Hepatol. 2019 03; 17(4):657-665.e13.
    View in: PubMed
    Score: 0.015
  73. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.015
  74. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018 09; 113(9):1310.
    View in: PubMed
    Score: 0.015
  75. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.015
  76. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018 08; 113(8):1148-1155.
    View in: PubMed
    Score: 0.015
  77. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2018 10; 16(10):1598-1606.e4.
    View in: PubMed
    Score: 0.015
  78. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic?Variants. Gastroenterology. 2018 04; 154(5):1273-1281.e3.
    View in: PubMed
    Score: 0.015
  79. Alcohol, smoking and risk of oesophago-gastric cancer. Best Pract Res Clin Gastroenterol. 2017 Oct; 31(5):509-517.
    View in: PubMed
    Score: 0.014
  80. Can We Accurately Predict Survival in Patients With Perihilar Cholangiocarcinoma? Clin Gastroenterol Hepatol. 2017 12; 15(12):1860-1862.
    View in: PubMed
    Score: 0.014
  81. Obesity and Risk of Nonalcoholic Fatty Liver Disease: A Comparison of Bioelectrical Impedance Analysis and Conventionally-Derived Anthropometric Measures. Clin Gastroenterol Hepatol. 2017 12; 15(12):1965-1967.
    View in: PubMed
    Score: 0.014
  82. High Negative Predictive Value, Low Prevalence, and Spectrum Effect: Caution in the Interpretation. Clin Gastroenterol Hepatol. 2017 09; 15(9):1355-1358.
    View in: PubMed
    Score: 0.014
  83. External Validation of the Michigan Barrett's Esophagus Prediction Tool. Clin Gastroenterol Hepatol. 2017 07; 15(7):1124-1126.
    View in: PubMed
    Score: 0.014
  84. Rising Incidence of Colorectal Cancer Among Young Hispanics in Texas. J Clin Gastroenterol. 2017 01; 51(1):34-42.
    View in: PubMed
    Score: 0.014
  85. Risk Profiles for Barrett's Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLoS One. 2016; 11(12):e0169250.
    View in: PubMed
    Score: 0.014
  86. Shiftwork Is Not Associated with Increased Risk of NAFLD: Findings from the National Health and Nutrition Examination Survey. Dig Dis Sci. 2017 02; 62(2):526-533.
    View in: PubMed
    Score: 0.014
  87. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):122-132.
    View in: PubMed
    Score: 0.014
  88. Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2017 02; 15(2):310-312.
    View in: PubMed
    Score: 0.014
  89. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. Am J Gastroenterol. 2016 11; 111(11):1528-1535.
    View in: PubMed
    Score: 0.013
  90. Prediction Models for Gastrointestinal and Liver Diseases: Too Many Developed, Too Few Validated. Clin Gastroenterol Hepatol. 2016 12; 14(12):1678-1680.
    View in: PubMed
    Score: 0.013
  91. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. Curr Opin Gastroenterol. 2016 07; 32(4):319-24.
    View in: PubMed
    Score: 0.013
  92. Inverse Association Between Gluteofemoral Obesity and Risk of?Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016 10; 14(10):1412-1419.e3.
    View in: PubMed
    Score: 0.013
  93. Weight Change and Weight Cycling Are?Not?Associated With Risk of Barrett's?Esophagus. Clin Gastroenterol Hepatol. 2016 12; 14(12):1839-1840.
    View in: PubMed
    Score: 0.013
  94. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016 Apr; 41:88-95.
    View in: PubMed
    Score: 0.013
  95. Coffee or Tea, Hot or Cold, Are Not Associated With Risk of Barrett's Esophagus. Clin Gastroenterol Hepatol. 2016 May; 14(5):769-72.
    View in: PubMed
    Score: 0.013
  96. Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Dig Dis Sci. 2016 Apr; 61(4):1139-47.
    View in: PubMed
    Score: 0.013
  97. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
    View in: PubMed
    Score: 0.013
  98. Unravelling the Riddle of Gastroesophageal Reflux Disease, Obesity, and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2273-5.
    View in: PubMed
    Score: 0.012
  99. Mendelian randomization study of height and risk of colorectal cancer. Int J Epidemiol. 2015 Apr; 44(2):662-72.
    View in: PubMed
    Score: 0.012
  100. Mendelian Randomization Study of Body Mass Index and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015 Jul; 24(7):1024-31.
    View in: PubMed
    Score: 0.012
  101. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2225-32.
    View in: PubMed
    Score: 0.012
  102. Metabolic syndrome and the risk of Barrett's oesophagus in white males. Aliment Pharmacol Ther. 2015 Jun; 41(11):1182-9.
    View in: PubMed
    Score: 0.012
  103. Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus. Best Pract Res Clin Gastroenterol. 2015 Feb; 29(1):41-50.
    View in: PubMed
    Score: 0.012
  104. The effect of obesity on pregnancy outcomes among Australian Indigenous and non-Indigenous women. Med J Aust. 2014 Nov 17; 201(10):592-5.
    View in: PubMed
    Score: 0.012
  105. Obesity and risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014 Nov; 106(11).
    View in: PubMed
    Score: 0.012
  106. Alcohol and the risk of Barrett's esophagus: a pooled analysis from the International BEACON Consortium. Am J Gastroenterol. 2014 Oct; 109(10):1586-94.
    View in: PubMed
    Score: 0.012
  107. Effects of physical activity on melatonin levels in previously sedentary men and women. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1696-9.
    View in: PubMed
    Score: 0.011
  108. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014 Mar; 48(3):218-23.
    View in: PubMed
    Score: 0.011
  109. Risk of esophageal adenocarcinoma decreases with height, based on consortium analysis and confirmed by Mendelian randomization. Clin Gastroenterol Hepatol. 2014 Oct; 12(10):1667-76.e1.
    View in: PubMed
    Score: 0.011
  110. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol. 2014 Aug; 12(8):1267-71.
    View in: PubMed
    Score: 0.011
  111. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci. 2014 Jan; 59(1):108-16.
    View in: PubMed
    Score: 0.011
  112. Can we really predict risk of cancer? Cancer Epidemiol. 2013 Aug; 37(4):349-52.
    View in: PubMed
    Score: 0.011
  113. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol. 2013 Jun; 108(6):915-22.
    View in: PubMed
    Score: 0.011
  114. A model to determine absolute risk for esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):138-44.e2.
    View in: PubMed
    Score: 0.010
  115. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012 Dec; 23(12):3155-3162.
    View in: PubMed
    Score: 0.010
  116. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res (Phila). 2012 Sep; 5(9):1115-23.
    View in: PubMed
    Score: 0.010
  117. The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. Int J Cancer. 2012 Sep 01; 131(5):E759-68.
    View in: PubMed
    Score: 0.010
  118. Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. Cancer Causes Control. 2012 Apr; 23(4):555-64.
    View in: PubMed
    Score: 0.010
  119. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther. 2011 Nov; 34(10):1235-44.
    View in: PubMed
    Score: 0.010
  120. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer. 2012 May 15; 130(10):2407-16.
    View in: PubMed
    Score: 0.009
  121. Maternal smoking during pregnancy among Aboriginal women in New South Wales is linked to social gradient. Aust N Z J Public Health. 2011 Aug; 35(4):337-42.
    View in: PubMed
    Score: 0.009
  122. Lifetime alcohol consumption and risk of Barrett's Esophagus. Am J Gastroenterol. 2011 Jul; 106(7):1220-30.
    View in: PubMed
    Score: 0.009
  123. Barrett's esophagus-associated genetic loci in African Americans: a case-control study using the All of Us Research Program. Eur J Gastroenterol Hepatol. 2026 Jun 01; 38(6):684-690.
    View in: PubMed
    Score: 0.006
  124. AGA Clinical Practice Guideline on Surveillance of Barrett's Esophagus. Gastroenterology. 2025 Nov; 169(6):1184-1231.
    View in: PubMed
    Score: 0.006
  125. HES V2.0 validation and performance compared to GALAD and ASAP in the HEDS cohort. J Hepatol. 2026 Mar; 84(3):578-586.
    View in: PubMed
    Score: 0.006
  126. Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits. Int J Cancer. 2026 Mar 01; 158(5):1193-1203.
    View in: PubMed
    Score: 0.006
  127. Comparing the performance of 3 sarcopenia definitions for predicting adverse events prior to liver transplant. Hepatol Commun. 2025 Jun 01; 9(6).
    View in: PubMed
    Score: 0.006
  128. A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol. BMC Health Serv Res. 2025 May 06; 25(1):645.
    View in: PubMed
    Score: 0.006
  129. A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus. Dig Dis Sci. 2025 Aug; 70(8):2739-2749.
    View in: PubMed
    Score: 0.006
  130. High Risk of Persistence and Risk of Dysplasia After Diagnosis of Ultrashort Barrett's Esophagus. Am J Gastroenterol. 2025 Nov 01; 120(11):2520-2528.
    View in: PubMed
    Score: 0.006
  131. Myosteatosis Is Associated With Frailty and Poor Physical Function in Patients Undergoing Liver Transplant Evaluation: A Cohort Study. Clin Transplant. 2024 Dec; 38(12):e70034.
    View in: PubMed
    Score: 0.006
  132. Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.006
  133. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.006
  134. Baylor College of Medicine (BCM) model predicts recurrence after mucosectomy of colorectal lateral spreading tumors in European cohorts. Clin Res Hepatol Gastroenterol. 2024 10; 48(8):102460.
    View in: PubMed
    Score: 0.006
  135. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia. Gastroenterology. 2024 06; 166(6):1020-1055.
    View in: PubMed
    Score: 0.006
  136. Helicobacter pylori infection does not influence the progression from gastroesophageal reflux disease to Barrett's esophagus to esophageal adenocarcinoma. Minerva Gastroenterol (Torino). 2024 Dec; 70(4):454-462.
    View in: PubMed
    Score: 0.006
  137. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
    View in: PubMed
    Score: 0.006
  138. Geographic Variation in Late-Stage Cervical Cancer Diagnosis. JAMA Netw Open. 2023 11 01; 6(11):e2343152.
    View in: PubMed
    Score: 0.006
  139. A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients. Am J Gastroenterol. 2024 03 01; 119(3):505-511.
    View in: PubMed
    Score: 0.005
  140. Bioimpedance analysis predicts the etiology of cirrhosis in a prospective cohort study. Hepatol Commun. 2023 10 01; 7(10).
    View in: PubMed
    Score: 0.005
  141. New Model to Predict Recurrence After Endoscopic Mucosal Resection of Non-pedunculated Colonic Polyps?=?20?mm. Dig Dis Sci. 2023 10; 68(10):3935-3942.
    View in: PubMed
    Score: 0.005
  142. Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies. Dig Dis Sci. 2023 09; 68(9):3732-3744.
    View in: PubMed
    Score: 0.005
  143. Association of Diet Quality with Metabolic (Dysfunction) Associated Fatty Liver Disease in Veterans in Primary Care. Nutrients. 2023 Jun 01; 15(11).
    View in: PubMed
    Score: 0.005
  144. Risk Stratification Model for Hepatocellular Cancer in Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3296-3304.e3.
    View in: PubMed
    Score: 0.005
  145. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 08; 21(9):2183-2192.
    View in: PubMed
    Score: 0.005
  146. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.005
  147. Evolution of endoscopic mucosal resection (EMR) technique and the reduced recurrence of large colonic polyps from 2012 to 2020. Scand J Gastroenterol. 2023 04; 58(4):435-440.
    View in: PubMed
    Score: 0.005
  148. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality. JAMA Netw Open. 2022 10 03; 5(10):e2234221.
    View in: PubMed
    Score: 0.005
  149. Limits of the AGA Practice Update for Barrett's Esophagus Screening: A Proposal for Electronic Health Record-Adaptable Risk Models. Clin Gastroenterol Hepatol. 2023 Jul; 21(7):1963-1964.
    View in: PubMed
    Score: 0.005
  150. Development and Validation of the Houston-BEST, a Barrett's Esophagus Risk Prediction Model Adaptable to Electronic Health Records. Clin Gastroenterol Hepatol. 2023 08; 21(9):2424-2426.e0.
    View in: PubMed
    Score: 0.005
  151. GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. Gut. 2023 04; 72(4):612-623.
    View in: PubMed
    Score: 0.005
  152. Reduced frequency of high cholesterol levels among patients with intracerebral haemorrhage. J Clin Neurosci. 2002 Jul; 9(4):376-80.
    View in: PubMed
    Score: 0.005
  153. Risk-based decision-making related to preprocedural coronavirus disease 2019 testing in the setting of GI endoscopy: management of risks, evidence, and behavioral health economics. Gastrointest Endosc. 2022 11; 96(5):735-742.e3.
    View in: PubMed
    Score: 0.005
  154. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022 09; 163(3):649-658.e2.
    View in: PubMed
    Score: 0.005
  155. Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study. Blood Cancer J. 2022 05 25; 12(5):82.
    View in: PubMed
    Score: 0.005
  156. Perceptions of weight status and energy balance behaviors among patients with non-alcoholic fatty liver disease. Sci Rep. 2022 04 05; 12(1):5695.
    View in: PubMed
    Score: 0.005
  157. Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer J. 2022 02 24; 12(2):34.
    View in: PubMed
    Score: 0.005
  158. External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of U.S. veterans. Gastrointest Endosc. 2022 06; 95(6):1113-1122.
    View in: PubMed
    Score: 0.005
  159. Perceived Barriers to Weight Loss among Hispanic Patients with Non-alcoholic Fatty Liver Disease. Hisp Health Care Int. 2022 09; 20(3):171-178.
    View in: PubMed
    Score: 0.005
  160. Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
    View in: PubMed
    Score: 0.005
  161. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. Gut. 2022 06; 71(6):1053-1061.
    View in: PubMed
    Score: 0.005
  162. International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence. Am J Gastroenterol. 2021 05 01; 116(5):1072-1076.
    View in: PubMed
    Score: 0.005
  163. Prevalence and Predictors of Missed Dysplasia on Index Barrett's Esophagus Diagnosing Endoscopy in a Veteran Population. Clin Gastroenterol Hepatol. 2022 04; 20(4):e876-e889.
    View in: PubMed
    Score: 0.005
  164. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. Nat Commun. 2021 01 11; 12(1):246.
    View in: PubMed
    Score: 0.005
  165. Sex Differences in the Risk of Barrett's Esophagus Associated With the Metabolic Effects of Obesity. J Clin Gastroenterol. 2020 10; 54(9):795-800.
    View in: PubMed
    Score: 0.004
  166. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.004
  167. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2020 12; 159(6):2065-2076.e1.
    View in: PubMed
    Score: 0.004
  168. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 07; 66(7):2439-2451.
    View in: PubMed
    Score: 0.004
  169. Prevalence of Barrett's esophagus and performance of societal?screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointest Endosc. 2021 02; 93(2):409-419.e1.
    View in: PubMed
    Score: 0.004
  170. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021 01; 19(1):61-71.e15.
    View in: PubMed
    Score: 0.004
  171. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.004
  172. Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population. Clin Gastroenterol Hepatol. 2021 02; 19(2):269-276.e3.
    View in: PubMed
    Score: 0.004
  173. Risk Prediction Models for Barrett's Esophagus Discriminate Well and Are Generalizable in an External Validation Study. Dig Dis Sci. 2020 10; 65(10):2992-2999.
    View in: PubMed
    Score: 0.004
  174. Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. Clin Colorectal Cancer. 2020 06; 19(2):e49-e57.
    View in: PubMed
    Score: 0.004
  175. Decreasing Overall and Inappropriate Proton Pump Inhibitor Use:?Perspective From a Large Safety-Net Healthcare System. Clin Gastroenterol Hepatol. 2020 04; 18(4):763-766.e2.
    View in: PubMed
    Score: 0.004
  176. Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):427-433.
    View in: PubMed
    Score: 0.004
  177. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. Clin Gastroenterol Hepatol. 2020 11; 18(12):2701-2709.e3.
    View in: PubMed
    Score: 0.004
  178. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.004
  179. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer. 2019 12 01; 125(23):4210-4223.
    View in: PubMed
    Score: 0.004
  180. Incidence of AIDS-Related Kaposi Sarcoma in All 50 United States From 2000 to 2014. J Acquir Immune Defic Syndr. 2019 08 01; 81(4):387-394.
    View in: PubMed
    Score: 0.004
  181. Statin use and risk of liver cancer: Evidence from two population-based studies. Int J Cancer. 2020 03 01; 146(5):1250-1260.
    View in: PubMed
    Score: 0.004
  182. Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Med. 2019 09; 20(8):567-570.
    View in: PubMed
    Score: 0.004
  183. External validation of a model to determine risk of progression of Barrett's oesophagus to neoplasia. Aliment Pharmacol Ther. 2019 05; 49(10):1274-1281.
    View in: PubMed
    Score: 0.004
  184. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. Clin Gastroenterol Hepatol. 2019 10; 17(11):2227-2235.e1.
    View in: PubMed
    Score: 0.004
  185. Diagnostics for Pleiotropy in Mendelian Randomization Studies: Global and Individual Tests for Direct Effects. Am J Epidemiol. 2018 12 01; 187(12):2672-2680.
    View in: PubMed
    Score: 0.004
  186. Missed Opportunities for Screening and Surveillance of Barrett's Esophagus in Veterans with Esophageal Adenocarcinoma. Dig Dis Sci. 2019 02; 64(2):367-372.
    View in: PubMed
    Score: 0.004
  187. Changing Trends in Colorectal Cancers (Detected by Screening, During Screening Intervals, or Associated With Nonadherence) Identify Possible Health Care System Quality Measures. Gastroenterology. 2019 02; 156(3):809-811.
    View in: PubMed
    Score: 0.004
  188. Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Gastroenterology. 2019 01; 156(1):43-45.
    View in: PubMed
    Score: 0.004
  189. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.004
  190. Long-term follow up of patients with obscure gastrointestinal bleeding examined with video capsule endoscopy. Medicine (Baltimore). 2018 Jul; 97(29):e11429.
    View in: PubMed
    Score: 0.004
  191. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies. Aliment Pharmacol Ther. 2018 07; 48(1):55-64.
    View in: PubMed
    Score: 0.004
  192. Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clin Gastroenterol Hepatol. 2019 02; 17(3):560-562.e2.
    View in: PubMed
    Score: 0.004
  193. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018 08; 155(2):316-326.e6.
    View in: PubMed
    Score: 0.004
  194. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. Br J Cancer. 2018 04; 118(8):1123-1129.
    View in: PubMed
    Score: 0.004
  195. Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2018 08; 16(8):1229-1236.e4.
    View in: PubMed
    Score: 0.004
  196. Factors That Contribute to Indeterminate Results From the?QuantiFERON-TB Gold In-Tube Test in Patients With?Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 10; 16(10):1616-1621.e1.
    View in: PubMed
    Score: 0.004
  197. Impact of cap-assisted colonoscopy on the learning curve and quality in colonoscopy: a randomized controlled trial. Gastrointest Endosc. 2018 Mar; 87(3):723-732.e3.
    View in: PubMed
    Score: 0.004
  198. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.003
  199. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.003
  200. Clinical Manifestations of Helicobacter pylori-Negative Gastritis. Clin Gastroenterol Hepatol. 2017 Jul; 15(7):1037-1046.e3.
    View in: PubMed
    Score: 0.003
  201. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.003
  202. Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection. J Hepatol. 2017 02; 66(2):355-362.
    View in: PubMed
    Score: 0.003
  203. Prevalence of Celiac Disease Among Unsuspected Patients Presenting to Open Access Endoscopy. Clin Gastroenterol Hepatol. 2017 01; 15(1):137-139.
    View in: PubMed
    Score: 0.003
  204. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. Gut. 2017 10; 66(10):1739-1747.
    View in: PubMed
    Score: 0.003
  205. Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer. Cancer Epidemiol. 2016 10; 44:1-4.
    View in: PubMed
    Score: 0.003
  206. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016 06; 45(3):884-95.
    View in: PubMed
    Score: 0.003
  207. A Model to Predict the Risk of Keratinocyte Carcinomas. J Invest Dermatol. 2016 06; 136(6):1247-1254.
    View in: PubMed
    Score: 0.003
  208. Symptoms of Obstructive Sleep Apnea, Gastroesophageal Reflux and the Risk of Barrett's Esophagus in a Population-Based Case-Control Study. PLoS One. 2015; 10(6):e0129836.
    View in: PubMed
    Score: 0.003
  209. Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol. 2014 Dec; 109(12):1870-80.
    View in: PubMed
    Score: 0.003
  210. Five-year longitudinal assessment of the downstream impact on schistosomiasis transmission following closure of the Three Gorges Dam. PLoS Negl Trop Dis. 2012; 6(4):e1588.
    View in: PubMed
    Score: 0.002
  211. A 5-year longitudinal study of schistosomiasis transmission in Shian village, the Anning River Valley, Sichuan Province, the Peoples' Republic of China. Parasit Vectors. 2011 Mar 24; 4:43.
    View in: PubMed
    Score: 0.002
  212. Screen time and metabolic risk factors among adolescents. Arch Pediatr Adolesc Med. 2010 Jul; 164(7):643-9.
    View in: PubMed
    Score: 0.002
  213. Inter-rater reliability of stroke sub-type classification by neurologists and nurses within a community-based stroke incidence study. J Clin Neurosci. 2001 Jan; 8(1):14-7.
    View in: PubMed
    Score: 0.001
  214. Hypertension and stroke. J Hypertens. 1994 Aug; 12(8):865-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.